Open-Label Placebo May Reduce Fatigue in Cancer Survivors

Share this content:
Open-Label Placebo May Reduce Fatigue in Cancer Survivors
Open-Label Placebo May Reduce Fatigue in Cancer Survivors

MONDAY, Feb. 12, 2018 (HealthDay News) -- Open-label placebo (OLP) may reduce fatigue in cancer survivors, according to a study published online Feb. 9 in Scientific Reports.

Teri W. Hoenemeyer, Ph.D., from the University of Alabama at Birmingham, and colleagues compared OLP to treatment as usual (TAU) for cancer survivors with fatigue in a 21-day randomized controlled trial. This was followed by a 21-day study in which TAU participants received OLP and OLP participants were followed after discontinuing placebo. Seventy-four cancer survivors who completed treatment six months to 10 years prior to enrollment and reporting at least moderate fatigue were randomized to receive OLP or TAU.

The researchers found that participants randomized to OLP reported a 29 percent improvement in fatigue severity and a 39 percent improvement in fatigue-disrupted quality of life compared to those randomized to TAU. Reductions in fatigue of a similar magnitude were reported for TAU participants who elected to try OLP for 21 days after the main study, with reductions of 23 and 35 percent for fatigue severity and fatigue-disrupted quality of life, respectively.

"OLP may reduce fatigue symptom severity and fatigue-related quality of life disruption in cancer survivors," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »